Aligos Therapeutics (ALGS) reported second-quarter 2026 financial results and recent business updates, including progress for pevifoscorvir sodium and ALG-170675 in chronic hepatitis B virus infection.
The company reported a net loss of $1.5 million, or $0.14 per basic and diluted share, for the three months ended June 30, 2026. Cash, cash equivalents and investments totaled $30.4 million as of June 30, 2026, excluding a $25 million upfront payment received from Amoytop in July 2026.
- Pevifoscorvir sodium received Breakthrough Therapy Designation from China’s CDE for chronic HBV infection.
- The Phase 2 B-SUPREME study completed enrollment with 131 participants in the HBeAg+ cohort and 114 participants in the HBeAg- cohort.
- Topline data from both B-SUPREME cohorts are expected in late Q3 2027.
- Aligos entered an exclusive Greater China license deal with Amoytop for pevifoscorvir sodium, receiving a $25 million upfront payment and eligibility for up to $420 million in milestones.
- Amoytop received IND approval in China for ALG-170675, triggering a $3 million milestone payment expected in Q3 2026.
- Research and development expenses were $24.1 million in Q2 2026, compared with $14.0 million a year earlier.
$ALGS Hedge Fund Activity
We have seen 11 institutional investors add shares of $ALGS stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 216,646 shares (+1652.8%) to their portfolio in Q1 2026, for an estimated $1,609,679
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 140,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,040,200
- WOODLINE PARTNERS LP removed 111,807 shares (-38.7%) from their portfolio in Q1 2026, for an estimated $830,726
- TWO SIGMA INVESTMENTS, LP removed 57,556 shares (-71.4%) from their portfolio in Q1 2026, for an estimated $427,641
- VERITION FUND MANAGEMENT LLC removed 52,367 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $389,086
- UBS GROUP AG added 36,697 shares (+10081.6%) to their portfolio in Q1 2026, for an estimated $272,658
- JANE STREET GROUP, LLC removed 24,293 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $180,496
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
